Citius Pharmaceuticals, Inc. (CTXR)
After hours:
| Previous Close | 0.9309 |
| Open | 0.9561 |
| Bid | 0.9524 x 800 |
| Ask | 0.9601 x 400 |
| Day's Range | 0.9200 - 0.9600 |
| 52 Week Range | 0.4800 - 1.0700 |
| Volume | |
| Avg. Volume | 2,270,270 |
| Market Cap | 173.446M |
| Beta (5Y Monthly) | 1.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2300 |
| Earnings Date | Aug 12, 2024 - Aug 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.67 |
Simply Wall St.When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Turn A Profit?
Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would...
NewsfileBiotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates.Read the full article on In
NewsfileAnalysts Hunt for Undervalued Biotech Stocks
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 17, 2024) - Investorideas.com, a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates.Read the full article on Inv
